Germantown, MD., and Hilden, Germany – QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) announced today the proposal of two international leaders in life sciences and healthcare – Dr. Vera Kallmeyer, M.D., Ph.D., and Elizabeth E. Tallett – for election to its Supervisory Board.

The Supervisory Board will propose these two independent candidates based on their extensive experience in the life sciences and healthcare industries as well as their roles as directors and officers in various international companies.

Shareholders will vote on these and other proposals at the next Annual General Meeting scheduled for June 30, 2011, including the reappointment of all six current Supervisory Board members to one-year terms.

“We are very pleased to propose these two new highly skilled international executives for election to our Board,” said Prof. Dr. Detlev H. Riesner, Chairman of the Supervisory Board and co-founder of QIAGEN N.V., and Chairman of the Selection and Appointment Committee. “Their perspectives, international experience in healthcare and academic research as well as their diverse business backgrounds will be valuable resources to QIAGEN as we expand our leading position in sample and assay technologies and their use in research, applied markets and clinical diagnostics.”

Dr. Vera Kallmeyer, M.D., Ph.D., is a Consulting Professor in the Department of Neurosurgery at Stanford School of Medicine, where she teaches courses in biomedical innovation, translational medicine and entrepreneurship. She is the founder and managing partner of Equity4Health LLC, a financial advisory and investment firm. She was formerly chief financial officer and vice president of corporate development at Aviron Inc. (now Medimmune/AstraZeneca), where she led several successful financing rounds including the company’s initial public offering which helped fuel Aviron’s substantial growth. She also held positions in investment banking with Wasserstein Perella & Company and Flemings as well served in several roles in training and practice in neurosurgery and cardiology. Dr. Kallmeyer currently serves on the board of Elekta AB as well as the board of visitors of UC Davis Medical School. Dr. Kallmeyer holds degrees from the Friedrich Alexander University in Erlangen, Germany. She also attended Harvard Medical School and the Royal Postgraduate School in London, and received an MBA and a Certificate in Public Management from the Stanford Graduate School of Business.

Elizabeth E. Tallett is a respected leader with more than 30 years of experience in the pharmaceutical and biotechnology as well as broader healthcare and financial industries. Her senior management experience includes President and CEO of Transcell Technologies Inc., President of Centocor Pharmaceuticals, member of the Parke-Davis Executive Committee, and Director of Worldwide Strategic Planning for Warner-Lambert Company. Born and educated in England, she graduated from Nottingham University with dual first class honours degrees in mathematics and economics. Ms. Tallett is currently a Principal of Hunter Partners, LLC, a management company for early to mid-stage pharmaceutical, biotech and medical device companies. She is a member of the board of directors of Principal Financial Group, Inc., Coventry Health Care, Inc., Meredith Corp. and IntegraMed America, Inc. She is currently the Lead Director for both Principal and Coventry Health Care. Ms. Tallett was a founding board member of the Biotechnology Council of New Jersey, and is a Trustee of Solebury School in Pennsylvania.